Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Vor Biopharma

Request full access

Vor Biopharma is an immuno-oncology company developing novel therapies with broad potential for treating cancer

Boston, United StatesFounded 2016Biotech & Life Sciences

About Vor Biopharma

Vor Biopharma, accessible at vorbio.com, is a pioneering company in the biopharmaceutical sector, focusing on innovative treatments for blood cancers. The company’s unique approach aims to protect healthy cells while targeting and eliminating cancerous ones. This method has the potential to revolutionize the treatment of blood cancers, particularly Acute Myeloid Leukemia (AML).

Vor Biopharma serves patients suffering from blood cancers, their caregivers, and the broader medical community, including hospitals and oncology centers. The company operates in the highly specialized and competitive biopharmaceutical market, which is driven by the need for advanced and effective cancer treatments.

The business model of Vor Biopharma revolves around research and development (R&D) of novel therapies. They invest heavily in scientific research to develop their proprietary platform and pipeline of treatments. The company generates revenue through partnerships with other pharmaceutical companies, licensing agreements, and eventually, the commercialization of their therapies once they receive regulatory approval.

Vor Biopharma was founded by Dr. Siddhartha Mukherjee, a Pulitzer Prize-winning author, and is supported by a team of world-class leaders and advisors with extensive experience in global biopharma. The company emphasizes collaboration and cross-functional teamwork to advance its mission rapidly.

In summary, Vor Biopharma is dedicated to transforming blood cancer treatment through innovative approaches that protect healthy cells and target cancerous ones. Their business model is centered on R&D, partnerships, and eventual commercialization of their therapies.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2021
Employees
117
Open positions
16
Dealroom signal
63.6/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Oncology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
PRIVATE PLACEMENT VCOther financing Mar 2026 $75M — TCGX ↗
PRIVATE PLACEMENT NON VCOther financing Dec 2025 $150M — RA Capital Management · Logos Capital · Venrock Healthcare Capital Partners · Forbion Capital Partners ↗
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearRevenueGrowthEBITDAMargin
2026 $0 — −$34M —
2025 $0 — −$34M —
2024 $0 — −$118M —
2023 $0 — −$123M —
2022 $0 — −$91M —
2021 $0 — −$68M —
2020 $0 — −$43M —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Vor Biopharma website traffic

Latest recorded traffic for Vor Biopharma is 8.8K monthly website visits, down 48.2% over the last three months. Vor Biopharma's team grew 30% over the past year.

Latest monthly visits8.8K 3-month web change-48.2% 1-year team growth+30%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Vor Biopharma in the Boston ecosystem

Live from Dealroom

The Vor Biopharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

13 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

Other known investors7 additional known investors

  • Caligan Partners
  • Columbia University
  • Forbion Capital Partners
  • Frazier Life Sciences
  • Logos Capital
  • TCGX
  • Venrock Healthcare Capital Partners
Team profiled 17 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
4 countries with
team presence
🇺🇸 United States95.9%
🇮🇳 India2%
🇳🇱 Netherlands1%
🇫🇷 France1%
4 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Vor Biopharma on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Vor Biopharma’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.